These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 8586921)

  • 1. [Early diagnosis of hepatocellular carcinoma by serum AFP and PIVKA-II analysis].
    Aoyagi Y; Yanagi M; Asakura H
    Nihon Naika Gakkai Zasshi; 1995 Dec; 84(12):2003-7. PubMed ID: 8586921
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinical signification and evaluation of PIVKA-II in hepatocellular carcinoma].
    Matsushima A; Enomoto M; Yokoo Y; Arai M; Kobayashi T; Okuno F; Hirano Y; Sujita K; Eto S; Takagi T
    Rinsho Byori; 1989 Jun; 37(6):683-6. PubMed ID: 2477568
    [No Abstract]   [Full Text] [Related]  

  • 3. [Clinical evaluation of PIVKA-II as a marker of hepatocellular carcinoma].
    Arima K; Kodama T; Suga M; Sakamoto H; Ohe Y; Yachi A
    Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 2):3049-52. PubMed ID: 2476968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [PIVKA-II high-sensitivity PIVKA-II].
    Fujiyama S
    Nihon Rinsho; 2001 Oct; 59 Suppl 6():349-55. PubMed ID: 11761970
    [No Abstract]   [Full Text] [Related]  

  • 5. Sensitive measurement of serum abnormal prothrombin (PIVKA-II) as a marker of hepatocellular carcinoma.
    Tanaka Y; Kashiwagi T; Tsutsumi H; Nagasawa M; Toyama T; Ozaki S; Naito M; Ishibashi K; Azuma M
    Hepatogastroenterology; 1999; 46(28):2464-8. PubMed ID: 10522021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical usefulness of plasma PIVKA-II assay and its limitations in patients with hepatocellular carcinoma].
    Fujiyama S; Morishita T; Shibata J; Sato T
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1129-38. PubMed ID: 2471453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma.
    Cui R; Wang B; Ding H; Shen H; Li Y; Chen X
    Chin Med J (Engl); 2002 Jan; 115(1):42-5. PubMed ID: 11930656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Tumor markers of hepatocellular carcinoma].
    Kubo S; Matsukawa M
    Gan To Kagaku Ryoho; 2004 Dec; 31(13):2203-6. PubMed ID: 15628773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The clinical significance of PIVKA-II in hepatocellular carcinoma: a comparative study with alpha-fetoprotein: preliminary report].
    Sakon M; Monden M; Gotoh M; Kanai T; Umeshita K; Endoh W; Mori T
    Nihon Geka Gakkai Zasshi; 1989 Jul; 90(7):1129. PubMed ID: 2477681
    [No Abstract]   [Full Text] [Related]  

  • 10. [Tumor markers for hepatocellular carcinoma].
    Tateishi R; Enooku K; Shiina S; Koike K
    Nihon Rinsho; 2012 May; 70(5):821-7. PubMed ID: 22620007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time courses of PIVKA-II and AFP levels after hepatic artery embolization and hepatic artery infusion against hepatocellular carcinoma: relation between the time course and tumor necrosis.
    Kishi K; Sonomura T; Mitsuzane K; Nishida N; Kimura M; Satoh M; Yamada R; Kodama N; Kinoshita M; Tanaka H
    Radiat Med; 1992; 10(5):189-95. PubMed ID: 1279748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma].
    Yamashiki M; Kosaka Y
    Rinsho Byori; 1989 Feb; 37(2):118-21. PubMed ID: 2471846
    [No Abstract]   [Full Text] [Related]  

  • 13. Abnormal prothrombin (PIVKA-II) and hepatocellular carcinoma.
    Okuda H; Nakanish T; Furukawa M; Yamagata H; Obata H
    Trop Gastroenterol; 1991; 12(2):59-66. PubMed ID: 1719681
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma.
    Aoyagi Y; Oguro M; Yanagi M; Mita Y; Suda T; Suzuki Y; Hata K; Ichii K; Asakura H
    Cancer; 1996 May; 77(9):1781-6. PubMed ID: 8646674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of serum PIVKA-II (DCP) determination for differentiation between benign and malignant liver diseases.
    Lamerz R; Runge M; Stieber P; Meissner E
    Anticancer Res; 1999; 19(4A):2489-93. PubMed ID: 10470180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma abnormal prothrombin levels in patients with small hepatocellular carcinoma.
    Tanabe Y; Ohnishi K; Nomura F; Iida S
    Am J Gastroenterol; 1988 Dec; 83(12):1386-9. PubMed ID: 2461655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Optimal cut-off value of PIVKA-II for diagnosis of hepatocellular carcinoma--using ROC curve].
    Kim MJ; Bae KW; Seo PJ; Jeong IK; Kim JH; Lee BH; Bang KT; Kim DW; Song IH
    Korean J Hepatol; 2006 Sep; 12(3):404-11. PubMed ID: 16998292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical significance of des-gamma-carboxy prothrombin assay as a tumor marker].
    Yamano M
    Nihon Rinsho; 1990 Feb; 48 Suppl():999-1002. PubMed ID: 1693989
    [No Abstract]   [Full Text] [Related]  

  • 19. [Evaluation of plasma PIVKA-II as a new marker for hepatocellular carcinoma].
    Tada H; Kagawa K; Hikita H; Takeuchi T; Ohta Y; Fukui S; Shintani H; Deguchi T; Okanoue T; Takino T
    Gan No Rinsho; 1989 Apr; 35(5):564-70. PubMed ID: 2469809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical evaluation of PIVKA-II in patients with hepatocellular carcinoma. Detection of PIVKA-II by EIA using anti-PIVKA-II monoclonal antibody].
    Ohtani M; Ido K; Kawamoto C; Kimura K
    Rinsho Byori; 1989 Apr; 37(4):405-9. PubMed ID: 2545953
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.